We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-8.33%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$219M
AUM Growth
-$58.2M
Cap. Flow
-$26.3M
Cap. Flow %
-11.97%
Top 10 Hldgs %
60.72%
Holding
71
New
8
Increased
9
Reduced
20
Closed
15
Avg Time Held
1.5 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$8.71M
2
CCXI icon
ChemoCentryx, Inc.
CCXI
+$8.07M
3
PTCT icon
PTC Therapeutics
PTCT
+$7.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.64M
5
LLY icon
Eli Lilly
LLY
+$2.75M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.8M
2
STML
Stemline Therapeutics, Inc.
STML
+$10.3M
3
ILMN icon
Illumina
ILMN
+$8.32M
4
GILD icon
Gilead Sciences
GILD
+$3.87M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.58M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$127B
$18.5M 8.44%
77,822
-15,600
-17% -$3.58M
2016 Q4
13 quarters
GILD icon
2
Gilead Sciences
GILD
$194B
$17.7M 8.08%
237,284
-56,000
-19% -$3.87M
2016 Q4
13 quarters
BIIB icon
3
Biogen
BIIB
$34.4B
$14.5M 6.59%
45,700
– –
2018 Q4
5 quarters
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$10.6B
$14.3M 6.54%
169,784
+65,500
+63% +$5.64M
2016 Q4
13 quarters
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$3.29B
$14.2M 6.49%
337,000
+1,000
+0.3% +$41.2K
2018 Q3
6 quarters
AMGN icon
6
Amgen
AMGN
$234B
$13.4M 6.1%
66,000
– –
2018 Q4
5 quarters
PTCT icon
7
PTC Therapeutics
PTCT
$4.94B
$12M 5.46%
269,000
+155,000
+136% +$7.8M
2019 Q1
4 quarters
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.7M 5.32%
394,000
+4,000
+1% +$135K
2016 Q4
13 quarters
NBIX icon
9
Neurocrine Biosciences
NBIX
$13.8B
$9.29M 4.23%
107,300
-26,000
-20% -$2.54M
2017 Q3
10 quarters
CCXI icon
10
DELISTED
ChemoCentryx, Inc.
CCXI
$7.63M 3.48%
+190,000
New +$8.07M
2020 Q1
0 quarters
INCY icon
11
Incyte
INCY
$22.9B
$7.29M 3.32%
99,500
+35,500
+55% +$2.68M
2016 Q4
13 quarters
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$6.96M 3.17%
281,797
+239,097
+560% +$8.71M
2018 Q3
6 quarters
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
$6.61M 3.01%
73,641
-12,500
-15% -$1.23M
2016 Q4
13 quarters
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
$6.56M 2.99%
56,900
-7,100
-11% -$786K
2017 Q1
12 quarters
MRK icon
15
Merck
MRK
$360B
$6.4M 2.92%
87,194
+210
+0.2% +$16.5K
2019 Q4
1 quarter
HALO icon
16
Halozyme
HALO
$13.8B
$5.53M 2.52%
307,633
– –
2016 Q4
13 quarters
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.37M 1.54%
43,900
+8,000
+22% +$717K
2019 Q1
4 quarters
LLY icon
18
Eli Lilly
LLY
$1.12T
$2.77M 1.26%
+20,000
New +$2.75M
2020 Q1
0 quarters
SRPT icon
19
Sarepta Therapeutics
SRPT
$1.81B
$2.74M 1.25%
28,100
-12,000
-30% -$1.37M
2017 Q2
11 quarters
IONS icon
20
Ionis Pharmaceuticals
IONS
$7.14B
$2.54M 1.16%
53,781
– –
2017 Q1
12 quarters
ALNY icon
21
Alnylam Pharmaceuticals
ALNY
$31B
$2.42M 1.11%
22,300
-21,000
-48% -$2.42M
2017 Q3
10 quarters
ENTA icon
22
Enanta Pharmaceuticals
ENTA
$323M
$2.38M 1.09%
+46,500
New +$2.48M
2020 Q1
0 quarters
EXEL icon
23
Exelixis
EXEL
$15.4B
$1.78M 0.81%
103,534
– –
2016 Q4
13 quarters
KALV icon
24
DELISTED
KalVista Pharmaceuticals
KALV
$1.73M 0.79%
227,433
-50,000
-18% -$675K
2016 Q4
13 quarters
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$1.62M 0.74%
18,000
-39,000
-68% -$3.03M
2019 Q1
4 quarters
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2020 Portfolio in Review

As of Q1 2020, International Biotechnology Trust held 71 positions worth $219M, down 21% from $278M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

International Biotechnology Trust withdrew a net $26.3M in Q1 2020, closing 15 positions and reducing 20 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $10.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in ChemoCentryx, Inc. worth $7.63M.

  • International Biotechnology Trust's largest Q1 2020 buy was ChemoCentryx, Inc.: 190,000 shares worth $7.63M.
  • International Biotechnology Trust added most to Zogenix, Inc. in Q1 2020, an estimated $8.71M increase.
  • International Biotechnology Trust's biggest Q1 2020 reduction was Gilead Sciences, cutting an estimated $3.87M.
  • International Biotechnology Trust fully exited Regeneron Pharmaceuticals in Q1 2020, selling an estimated $10.8M.
  • International Biotechnology Trust's ten largest holdings make up 61% of its $219M portfolio in Q1 2020.
  • International Biotechnology Trust opened 8 new positions and closed 15 in Q1 2020.
  • International Biotechnology Trust's portfolio value fell 21% quarter-over-quarter to $219M.

Based on International Biotechnology Trust's 13F filing for Q1 2020, filed 18 May 2020.